Progress in medicinal chemistry. Volume 44 /
The perceived lack of drug discovery productivity in recent times has led to much debate in the pharmaceutical/biotechnology industry as escalating R & D costs are not being matched by increased output. Few observers doubt that selecting the right targets, ie those which are critical to disease...
| Άλλοι συγγραφείς: | , |
|---|---|
| Μορφή: | Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Amsterdam ; Boston :
Elsevier,
2006.
|
| Σειρά: | Progress in Medicinal Chemistry ;
v. 44. |
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
| Περίληψη: | The perceived lack of drug discovery productivity in recent times has led to much debate in the pharmaceutical/biotechnology industry as escalating R & D costs are not being matched by increased output. Few observers doubt that selecting the right targets, ie those which are critical to disease pathology and are 'druggable', is the best starting point for improved productivity. The seven chapters of this volume describe recent progress towards drugs acting at a range of 'druggable' targets. One chapter addresses kinases, one covers an ion channel, two proteases are featured and three of the chapt. |
|---|---|
| Φυσική περιγραφή: | 1 online resource. |
| Βιβλιογραφία: | Includes bibliographical references and indexes. |
| ISBN: | 0080462103 9780080462103 0444517375 9780444517371 1280641614 9781280641619 |
